Novartis Gets Positive CHMP Opinion For Leqvio For Patients With Hypercholesterolemia - Quick Facts

Swiss drug major Novartis AG (NVS) announced Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing authorization of Leqvio (inclisiran) for the treatment of adults with hypercholesterolemia or mixed dyslipidemia.

from RTT - Biotech https://ift.tt/3j2myN5
via IFTTT